Robinson Chandler
SEC CIK 1727334 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MNPR | Monopar Therapeutics | CEO, Dir | 103.4K | — | $672.0K | 50 | 2021-06-30 | 2026-06-30 |
Most active insiders at MNPR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Tsuchimoto Kim R | Dir | — | $911.1K |
| 2 | Anderson Raymond | Dir | — | $703.0K |
| 3 | KLAUSNER ARTHUR J | Dir | — | $343.9K |
| 4 | Vu Quan Anh | CFO | $104.9K | — |
| 5 | RIOUX PATRICE | Acting Chief Medical Off | — | $111.26 |
| 6 | Cittadine Andrew | COO | — | — |
| 7 | Hendricks Diane | 10% | — | — |
| 8 | Robinson Chandler | CEO, Dir | — | — |
Transactions 50
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-02 19:38 | 2026-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +12.9K | 103.4K | +14% | — |
| D | 2026-07-02 19:38 | 2026-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $92.59 | -4,084 | 99.3K | -4% | -$378.1K |
| D | 2026-04-02 15:03 | 2026-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +6,732 | 92.5K | +8% | — |
| D | 2026-04-02 15:03 | 2026-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $54.79 | -1,972 | 90.5K | -2% | -$108.0K |
| I | 2026-01-30 | 2025-01-28 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | J - Other | $0.00 | +62.8K | 62.8K | New | $0 |
| D | 2026-01-05 | 2025-12-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +8,724 | 88.3K | +11% | — |
| D | 2026-01-05 | 2025-12-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $65.30 | -2,558 | 85.7K | -3% | -$167.0K |
| D | 2025-10-02 | 2025-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +8,726 | 82.2K | +12% | — |
| D | 2025-10-02 | 2025-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $81.67 | -2,646 | 79.6K | -3% | -$216.1K |
| D | 2025-07-16 | 2025-07-14 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | X - OptEx | $0.01 | +16.8K | 90.3K | +23% | +$168 |
| D | 2025-07-16 | 2025-07-14 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | S - Sale+OE | $40.00 | -16.8K | 73.5K | -19% | -$672.0K |
| D | 2025-07-02 | 2025-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +13.3K | 79.3K | +20% | — |
| D | 2025-07-02 | 2025-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $35.78 | -5,865 | 73.5K | -7% | -$209.8K |
| D | 2025-04-02 | 2025-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +4,106 | 67.2K | +7% | — |
| D | 2025-04-02 | 2025-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $36.41 | -1,204 | 66.0K | -2% | -$43.8K |
| D | 2025-03-07 | 2025-03-04 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +6,002 | 64.8K | +10% | — |
| D | 2025-03-07 | 2025-03-04 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $31.70 | -1,759 | 63.1K | -3% | -$55.8K |
| D | 2025-01-02 | 2024-12-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +4,895 | 61.1K | +9% | — |
| D | 2025-01-02 | 2024-12-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $22.00 | -2,209 | 58.8K | -4% | -$48.6K |
| D | 2024-10-02 | 2024-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $6.74 | -1,918 | 56.2K | -3% | -$12.9K |
| D | 2024-10-02 | 2024-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +4,895 | 58.1K | +9% | — |
| D | 2024-07-02 | 2024-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $0.73 | -8,684 | 265.9K | -3% | -$6,339 |
| D | 2024-07-02 | 2024-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +24.5K | 274.6K | +10% | — |
| D | 2024-05-30 | 2024-05-28 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | X - OptEx | $0.00 | +84.0K | 250.1K | +51% | $0 |
| D | 2024-04-02 | 2024-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $0.68 | -7,172 | 166.1K | -4% | -$4,877 |
| D | 2024-04-02 | 2024-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +24.5K | 173.3K | +16% | — |
| DM | 2024-01-03 | 2023-12-31+ | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $0.34 | -10.8K | 148.8K | -7% | -$3,671 |
| DM | 2024-01-03 | 2023-12-31+ | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +31.2K | 152.9K | +26% | — |
| D | 2023-10-03 | 2023-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $0.62 | -7,172 | 128.4K | -5% | -$4,447 |
| D | 2023-10-03 | 2023-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +24.5K | 135.6K | +22% | — |
| D | 2023-07-03 | 2023-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $0.86 | -10.3K | 111.1K | -8% | -$8,831 |
| D | 2023-07-03 | 2023-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +35.0K | 121.4K | +41% | — |
| D | 2023-04-04 | 2023-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +13.9K | 90.6K | +18% | — |
| D | 2023-04-04 | 2023-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $1.39 | -4,286 | 86.4K | -5% | -$5,958 |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +20.6K | 77.1K | +37% | — |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $2.37 | -7,141 | 72.3K | -9% | -$16.9K |
| D | 2022-10-03 | 2022-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +13.9K | 67.3K | +26% | — |
| D | 2022-10-03 | 2022-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $1.52 | -4,077 | 63.2K | -6% | -$6,197 |
| D | 2022-07-01 | 2022-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +23.9K | 60.4K | +65% | — |
| D | 2022-07-01 | 2022-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $2.30 | -6,999 | 53.4K | -12% | -$16.1K |
| D | 2022-04-01 | 2022-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +3,941 | 37.7K | +12% | — |
| D | 2022-04-01 | 2022-03-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $2.55 | -1,155 | 36.5K | -3% | -$2,945 |
| D | 2022-01-04 | 2022-01-01 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $3.21 | -2,327 | 33.7K | -6% | -$7,470 |
| D | 2022-01-04 | 2022-01-01 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +6,724 | 36.1K | +23% | — |
| D | 2022-01-04 | 2021-12-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +3,941 | 30.7K | +15% | — |
| D | 2022-01-04 | 2021-12-31 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $3.21 | -1,364 | 29.3K | -4% | -$4,378 |
| D | 2021-10-01 | 2021-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $4.87 | -1,155 | 26.8K | -4% | -$5,625 |
| D | 2021-10-01 | 2021-09-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +3,941 | 27.9K | +16% | — |
| D | 2021-07-02 | 2021-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | F - Tax | $5.89 | -2,310 | 24.0K | -9% | -$13.6K |
| D | 2021-07-02 | 2021-06-30 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO, Dir | M - OptEx | — | +7,883 | 26.3K | +43% | — |
Purchase Sale Sale after option exercise All abbreviations